Intarcia Therapeutics IPO

Intarcia is a biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease.

Who are Intarcia Therapeutics's major investors?

New Enterprise Associates

GGV Capital

Venrock

Foresite Capital

Farallon Capital Management

Fred Alger Management

New Leaf Venture Partners

Quilvest

RA Capital

Date	Funding Round	Funding Raised	Price per Share	IPO Valuation
9/15/2016	Series EE	$475.68MM raised	$XXX.XX	$XXX.XX
7/4/2014	Series DD	$200MM raised	$XXX.XX	$XXX.XX
11/15/2012	Series CC	$210MM raised	$XXX.XX	$XXX.XX
1/14/2010	Series BB-3	$7.87MM raised	$XXX.XX	$XXX.XX
4/28/2008	Series BB-2	$24.99MM raised	$XXX.XX	$XXX.XX
3/9/2007	Series BB-1	$23.84MM raised	$XXX.XX	$XXX.XX
12/1/2004	Series AA	$19.08MM raised	$XXX.XX	$XXX.XX

Based on primary financings

Intarcia Therapeutics has raised $961.46MM to date.

Intarcia Therapeutics was founded in 1995.

Updated on: Jun 12, 2022